The correlation of the international association for the study of lung cancer (IASLC)/American thoracic society (ATS)/European respiratory society (ERS) classification with prognosis and egfr mutation in lung adenocarcinoma

Annals of Thoracic Surgery

Volumn 98, Issue 2, 2014, Pages 453-458

  Yanagawa, Naoki ^a   Shiono, Satoshi ^a   Abiko, Masami ^a   Ogata, Shin Ya ^a   Sato, Toru ^a   Tamura, Gen ^a  

^a Yamagata Prefectural Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ACINAR CELL CARCINOMA; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INVASIVE ADENOCARCINOMA; JAPANESE (PEOPLE); LUNG ADENOCARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROPAPILLARY ADENOCARCINOMA; MINIMALLY INVASIVE ADENOCARCINOMA; MISSENSE MUTATION; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SEX DIFFERENCE; SOMATIC MUTATION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROGNOSIS; PULMONARY MEDICINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 84905584697     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2014.04.108     Document Type: Article

References (29)

1. W. Lilleby, G. Torlakovic, E. Torlakovic, E. Skovlund, and S.D. Fossa Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy Cancer 92 2001 311 319
2. A. Billis, M.S. Guimaraes, L.L. Freitas, L. Meirelles, L.A. Manga, and U. Ferreira The impact of the 2005 International Society of Urological Pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies J Urol 180 2008 548 552 discussion 552-3
3. H. Pereira, S.E. Pinder, and D.M. Sibbering et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma Histopathology 27 1995 219 226
4. G. D'Eredita', C. Giardina, M. Martellotta, T. Natale, and F. Ferrarese Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution Eur J Cancer 37 2001 591 596
5. C.W. Elston Classification and grading of invasive breast carcinoma Verh Dtsch Ges Pathol 89 2005 35 44
6. W.D. Travis, E. Brambilla, and H.K. Muller-Hermelin et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon
7. W.D. Travis, E. Brambilla, and M. Noguchi et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
8. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
9. J.G. Paez, P.A. Jänne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
10. K. Sugio, H. Uramoto, and K. Ono et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking Br J Cancer 94 2006 896 903
11. M. Maemondo, A. Inoue, and K. Kobayashi et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
12. A. Marchetti, C. Martella, and L. Felicioni et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 2005 857 865
13. M. Sonobe, T. Manabe, H. Wada, and F. Tanaka Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma Br J Cancer 93 2005 355 363
14. P.L. Sun, H. Seol, and H.J. Lee et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features J Thorac Oncol 7 2012 323 330
15. A. Yoshizawa, S. Sumiyoshi, and M. Sonobe et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients J Thorac Oncol 8 2013 52 61
16. K. Tsuta, M. Kawago, and E. Inoue et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations Lung Cancer 81 2013 371 376
17. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM classification of malignant tumors (UICC International Union Against Cancer) 7th edition 2009 Wiley-Blackwell Hoboken, NJ
18. H. Sakurai, A. Maeshima, and S. Watanabe et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis Am J Surg Pathol 28 2004 198 206
19. K. Naoki, K. Soejima, and H. Okamoto et al. The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing Int J Clin Oncol 16 2011 335 344
20. A. Yoshizawa, N. Motoi, and G.J. Riely et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Mod Pathol 24 2011 653 664
21. A. Warth, T. Muley, and M. Meister et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival J Clin Oncol 30 2012 1438 1446
22. P.A. Russell, Z. Wainer, G.M. Wright, M. Daniels, M. Conron, and R.A. Williams Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification J Thorac Oncol 6 2011 1496 1504
23. L. Xu, F. Tavora, R. Battafarano, and A. Burke Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society Am J Surg Pathol 36 2012 273 282
24. T. Woo, K. Okudela, and H. Mitsui et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases Pathol Int 62 2012 785 791
25. N. Yanagawa, S. Shiono, M. Abiko, S. Ogata, T. Sato, and G. Tamura New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma J Thorac Oncol 8 2013 612 618
26. A. Warth, A. Stenzinger, and A.C. von Brünneck et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas Eur Respir J 40 2012 1221 1227
27. E. Thunnissen, M.B. Beasley, and A.C. Borczuk et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study Mod Pathol 25 2012 1574 1583
28. Y. Nakazato, A.M. Maeshima, and Y. Ishikawa et al. Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma J Thorac Oncol 8 2013 736 743
29. N. Motoi, J. Szoke, and G.J. Riely et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis Am J Surg Pathol 32 2008 810 827